Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Recruiting

Phase 2

PosaconazolePosaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT04665037

Conditions

Invasive Fungal Infection

Eligibility Criteria

Sex: All

Age: 1 - 2

Healthy Volunteers: Not accepted

Interventions

Posaconazole IV 6 mg/kg

Posaconazole PFS 6 mg/kg

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-05-15.